Organogenesis Holdings Enters ATM Sales Agreement for up to $75M

What Happened Organogenesis Holdings Inc. announced on August 6, 2026 that it entered into an At-the-Market (ATM) Sales Agreement with BTIG, LLC and Citizens JMP Securities, LLC as sales agents. Under the agreement and a prospectus supplement dated August 6, 2026, the company may offer and sell up to $75,000,000 aggregate offering price of its Class A common stock, using its previously filed and effective Form S-3 shelf registration (filed Aug 8, 2024; declared effective Aug 15, 2024). The company is not required to sell any shares under the agreement.

Key Details

• Date of agreement: August 6, 2026; prospectus supplement filed same date.
• Maximum aggregate offering: up to $75,000,000 of Class A common stock.
• Agents: BTIG, LLC and Citizens JMP Securities, LLC; commission up to 3.0% of gross sales price.
• Sales may be made on Nasdaq or other trading markets as permitted by law; company can set limits and has no obligation to sell.
• Legal opinion from Foley Hoag LLP regarding the shares is included as an exhibit to the 8-K.

Why It Matters This ATM facility gives Organogenesis a flexible way to raise capital over time by selling shares into the market as needed, rather than through a single large offering. For investors, any future sales would increase shares outstanding and could dilute existing ownership; the timing, size and price of sales are at the company’s discretion and depend on market conditions. The commission rate and inclusion of a legal opinion are routine deal terms disclosed in the filing.